Zibotentan/Dapagliflozin

Phase 3

AstraZeneca PLC (AZN)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

10mo

AZNPhase 3$316.3B

Zibotentan/Dapagliflozin Phase 3 Results Expected

Zibotentan/Dapagliflozin• Chronic Kidney Disease With High Proteinuria1,835

Jan 22Estimated

CT.gov

00%

4mo

AZNPhase 2$316.3B

Zibotentan/Dapagliflozin Phase 2 Results Expected

Zibotentan/Dapagliflozin• Chronic Kidney Disease With High Proteinuria224

Jul 31Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Chronic Kidney Disease With High Proteinuria

View Full Landscape

Drug Information

Target Indication

Chronic Kidney Disease With High Proteinuria

Clinical Trial

NCT06087835

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AZN

AstraZeneca PLC

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

LinaclotidePhase 3

Irritable Bowel Syndrome With Constipation (IBS-C)

Enfortumab VedotinPhase 3

Muscle Invasive Bladder Cancer

Budesonide/albuterol metered-dose inhaler 160/180 μgPhase 3

Asthma, Exercise-Induced

Quetiapine fumarate (Seroquel) SRPhase 3

Affective Psychosis, Bipolar

(Osimertinib cohort, single-arm, open-label separate cohort)Phase 3

Carcinoma, Non-Small-Cell Lung

View full pipeline